Joseph Tuscano

Dr. Joseph Tuscano


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Autoimmunity Reviews
Verified
Journal Article
Closed access
GBGarrett F. Bass
Garrett F. Bass
ETEmily T. Tuscano
Emily T. Tuscano
JTJoseph Tuscano
Joseph Tuscano

20 November 2009 in Hepatology
Verified
Journal Article
Open access
PDF file
YMYuki Moritoki
Yuki Moritoki
ZLZhexiong Lian
Zhexiong Lian
KLKeith Lindor
Keith Lindor
JTJoseph Tuscano
Joseph Tuscano
KTKoichi Tsuneyama
Koichi Tsuneyama
MGM. Eric Gershwin
M. Eric Gershwin
The treatment of primary biliary cirrhosis (PBC) with conventional immunosuppressive drugs has been relatively disappointing and there have been few efforts in defining a role for the newer biological agents useful in rheumatoid arthritis and other systemic autoimmune diseases. In this study we took advantage of transforming growth factor-β (TGF-β) receptor II dominant negative (dnTGF-βRII) mice, a mouse model of autoimmune cholangitis, to address the therapeutic efficacy of B-cell depletion using anti-CD20. Mice were treated at either 4-6 weeks of age or beginning at 20-22 weeks of age with intraperitoneal injections of anti-CD20 every 2 weeks. We quantitated B-cell levels in all mice as well as antimitochondrial antibodies (AMA), serum and hepatic levels of proinflammatory cytokines, and histopathology of liver and colon. In mice whose treatment was initiated at 4-6 weeks of age, anti-CD20 therapy demonstrated a significantly lower incidence of liver inflammation associated with reduced numbers of activated hepatic CD8+ T cells. However, colon inflammation was exacerbated. In contrast, in mice treated at 20-22 weeks of age, anti-CD20 therapy had relatively little effect on either liver or colon disease. As expected, all treated animals had reduced levels of B cells, absence of AMA, and increased levels in sera of tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and chemokine (C-C motif) ligand (CCL2) (monocyte chemoattractant protein 1 [MCP-1]). Conclusion: These data suggest potential usage of anti-CD20 in early PBC resistant to other modalities, but raise a cautionary note regarding the use of anti-CD20 in inflammatory bowel disease. (HEPATOLOGY 2009.)

22 May 2013 in BioDrugs
Verified
Journal Article
Closed access
PDF file
LSLoretta Sullivan-Chang
Loretta Sullivan-Chang
RORobert T. O’dOnnell
Robert T. O’dOnnell
JTJoseph Tuscano
Joseph Tuscano

7 March 2014 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
JTJoseph Tuscano
Joseph Tuscano
MDMrinal Dutia
Mrinal Dutia
KCKaren Chee
Karen Chee
ABAnn Brunson
Ann Brunson
CRChristine Reed‐Pease
Christine Reed‐Pease
RORobert T. O'DOnnell
Robert T. O'DOnnell

13 May 2010 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JTJoseph Tuscano
Joseph Tuscano
SMShiloh M. Martin
Shiloh M. Martin
YMYunpeng Ma
Yunpeng Ma
WZWilliam Zamboni
William Zamboni
RORobert T. O'DOnnell
Robert T. O'DOnnell
Purpose: Non–Hodgkin's lymphoma (NHL) is the sixth most common cause of cancer death in the U.S. Pegylated liposomal doxorubicin (PLD) is a liposomal form of doxorubicin (DXR) that causes less toxicity than does free DXR. To further enhance efficacy and decrease toxicity, we conjugated HB22.7, an anti-CD22 monoclonal antibody to PLD, thus creating CD22-targeted immunoliposomal PLD (IL-PLD).

27 April 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Christoph VogelChristoph Vogel
Christoph Vogel
YIYasuhiro Ishihara
Yasuhiro Ishihara
CCClaire E. Campbell
Claire E. Campbell
SKSarah Y. Kado
Sarah Y. Kado
ACAimy Nguyen Chi
Aimy Nguyen Chi
JTJoseph Tuscano
Joseph Tuscano
The aryl hydrocarbon receptor (AhR) is known for mediating the toxicity of environmental pollutants such as dioxins and numerous dioxin-like compounds, and is associated with the promotion of various malignancies, including lymphoma. The aryl hydrocarbon receptor repressor (AhRR), a ligand-independent, transcriptionally inactive AhR-like protein is known to repress AhR signaling through its ability to compete with the AhR for dimerization with the AhR nuclear translocator (ARNT). While AhRR effectively blocks AhR signaling, several aspects of the mechanism of AhRR’s functions are poorly understood, including suppression of inflammatory responses and its putative role as a tumor suppressor. In a transgenic mouse that overexpresses AhRR (AhRR Tg) we discovered that these mice suppress 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)- and inflammation-induced tumor growth after subcutaneous challenge of EL4 lymphoma cells. Using mouse embryonic fibroblasts (MEF) we found that AhRR overexpression suppresses the AhR-mediated anti-apoptotic response. The AhRR-mediated inhibition of apoptotic resistance was associated with a suppressed expression of interleukin (IL)-1β and cyclooxygenase (COX)-2, which was dependent on activation of protein kinase A (PKA) and the CAAT-enhancer-binding protein beta (C/EBPβ). These results provide mechanistic insights into the role of the AhRR to suppress inflammation and highlight the AhRR as a potential therapeutic target to suppress tumor growth.